Novavax Inc SEC Filings

Welcome to our dedicated page for Novavax SEC filings (Ticker: NVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The Novavax, Inc. (NASDAQ: NVAX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Novavax is a vaccine-focused biotechnology company that reports on its financial condition, material agreements, capital structure and key product and partnership developments through forms such as 10-K, 10-Q and 8-K.

Current Reports on Form 8-K for Novavax frequently address material events tied to its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, the Matrix-M® adjuvant platform and major collaborations. Examples include disclosures about the collaboration and license agreement with Sanofi, marketing authorization transfers for Nuvaxovid in the European Union and United States that trigger milestone payments, amendments expanding Sanofi’s license to use Matrix-M in pandemic influenza vaccine candidates, and milestone payments and royalties associated with partners such as Takeda. Other 8-K filings describe site consolidation transactions in Maryland, non-cash impairment charges, and convertible senior note exchanges and issuances that shape the company’s capital structure.

Periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide detail on Novavax’s revenue components, including product sales, supply sales and licensing, royalties and other revenue, as well as research and development and selling, general and administrative expenses. They also expand on risk factors related to regulatory approvals, manufacturing, partnerships and market adoption of its vaccines.

On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in clear language. Users can quickly see key points from lengthy 10-K and 10-Q reports, understand the impact of 8-K announcements on partnerships and financing, and review information about potential equity issuance and debt obligations, including convertible senior notes. The filings page also surfaces insider and executive-related filings, such as Forms 3, 4 and 5, when available, to help track equity ownership changes.

All documents are updated in near real time as they are posted to the SEC’s EDGAR system, allowing investors and researchers to review Novavax’s official disclosures, assess how collaboration agreements and regulatory decisions affect the business, and follow the evolution of its vaccine and adjuvant platform through formal reporting.